The United Nations Secretary-General's High-Level Panel on Access to Medicines released their landmark report to address the tensions between public health, international human rights law, trade rules, and the justifiable rights of inventors in the context of health technologies.
YP-CDN commends the panel on their report that emphasized an urgent paradigm shift in transparency for medical R&D and need to move toward a system that de-links the costs of R&D from the price of medicines.
“A paradigm shift in transparency is needed to ensure that the costs of R&D, production, marketing, and distribution, as well as the end prices of health technologies are clear to consumers and governments,” said former President of Botswana, Festus Mogae. “Governments should require manufacturers and distributors of health technologies to disclose these costs and the details of any public funding received in the development of health technologies, including tax credits, subsidies, and grants.”
Read the full report here.